Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited (Q38218639)

31 August 2017

Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited (English)

1 reference

31 August 2017

0 references

3

1 reference

31 August 2017

4

1 reference

31 August 2017

Jan Hansen

1

1 reference

31 August 2017

Birgitte Brock

series ordinal

2

1 reference

31 August 2017

Jørgen Rungby

series ordinal

5

1 reference

31 August 2017

Michael Gejl

series ordinal

6

1 reference

31 August 2017

1 September 2014

1 reference

Reviews in Endocrine and Metabolic Disorders

31 August 2017

1 reference

31 August 2017

15

1 reference

31 August 2017

3

1 reference

31 August 2017

219-231

1 reference

https://scigraph.springernature.com/pub.10.1007/s11154-014-9286-8

31 August 2017

0 references

cites work

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Diabetes and decline in heart disease mortality in US adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Intensive glycemic control and cardiovascular disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Intensive versus conventional glucose control in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Identical mRNA for preproglucagon in pancreas and gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Neuroprotective properties of GLP-1: theoretical and practical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

The glucagon-like peptide-1 receptor--or not?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

The role of gut hormones in glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

New developments in the incretin concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Glucagon-like peptide 1(GLP-1) in biology and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

On the physiology of GIP and GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

The effect of glucagon-like peptide 1 on cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

GLP-1 and cardioprotection: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Myocardial fatty acid metabolism in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Role of changes in cardiac metabolism in development of diabetic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Impact of type 2 diabetes on myocardial insulin sensitivity to glucose uptake and perfusion in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Glucagon-like peptide-1 reduces contractile function and fails to boost glucose utilization in normal hearts in the presence of fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Myocardial insulin signaling and glucose transport are up-regulated in Goto-Kakizaki type 2 diabetic rats after ileal transposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Effects of DPP-4 inhibition on cardiac metabolism and function in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Saxagliptin Improves Glucose Tolerance but not Survival in a Murine Model of Dilated Cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Atrial natriuretic peptide increases glucose uptake during hypoxia in cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Cardiac substrate uptake and metabolism in obesity and type-2 diabetes: Role of sarcolemmal substrate transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

Decreased Myocardial Free Fatty Acid Uptake in Patients With Idiopathic Dilated Cardiomyopathy: Evidence of Relationship With Insulin Resistance and Left Ventricular Dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-014-9286-8

21 January 2018

Hibernating myocardium.

1 reference

12 December 2020

Heart glucose transport and transporters in rat heart: regulation by insulin, workload and glucose

1 reference

12 December 2020

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

1 reference

12 December 2020

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats

1 reference

12 December 2020

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart

1 reference

12 December 2020

The effect of epinephrine, glucagon, and the nutritional state on the oxidation of branched chain amino acids and pyruvate by isolated hearts and diaphragms of the rat.

1 reference

12 December 2020

A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.

1 reference

12 December 2020

Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease

1 reference

12 December 2020

The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart

1 reference

12 December 2020

Ischemia induces translocation of the insulin-responsive glucose transporter GLUT4 to the plasma membrane of cardiac myocytes

1 reference

12 December 2020

DPP4 deficiency exerts protective effect against H2O2 induced oxidative stress in isolated cardiomyocytes

1 reference

12 December 2020

GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice

1 reference

12 December 2020

In vivo glucose uptake and glucose transporter proteins GLUT1 and GLUT4 in heart and various types of skeletal muscle from streptozotocin-diabetic rats

1 reference

12 December 2020

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

12 December 2020

Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway

1 reference

12 December 2020

Role of insulin resistance in heart and skeletal muscle F-18 fluorodeoxyglucose uptake in patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines

1 reference

12 December 2020

Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis.

1 reference

12 December 2020

Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy

1 reference

12 December 2020

Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting

1 reference

12 December 2020

Glucagon-like peptide analogues for type 2 diabetes mellitus

1 reference

12 December 2020

Studies on the pharmacology of glucagon

1 reference

12 December 2020

10.1007/S11154-014-9286-8

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1020092150

0 references

Fatcat ID

release_uv4q7dooe5gjbhrygy62cqjcsy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uv4q7dooe5gjbhrygy62cqjcsy

24 November 2022

mapped directly with Wikidata item

1 reference